×

1) Publications
Hee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, Yu-Jung Kim, Sae-Won Han, Tae Min Kim, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Eui Kyu Chie, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh, Dae Seog Heo, In Ae Park, Yung-Jue Bang, Sung Whan Ha
Clinical outcome of central nervous system metastases from breast cancer: differences in survival
depending on systemic treatment J Neurooncol. 2012 Jan;106(2):303-13

Kim HJ, Park E, Lee TJ, Do JH, Cha YJ, Lee SJ.
A case of isolated light chain deposition disease in the duodenum J Korean Med Sci. 2012 Feb;27(2):
207-10.

Kim KT, Kim YB, Kim HJ, Cha YJ, Lee SJ, Park E.
Primary Spinal Natural Killer/T-cell Lymphoma Successfully Treated with Concurrent Chemoradiotherapy and Autologous Stem Cell Transplantation Spine (Phila Pa 1976). 2011 Nov 14.

Kim MJ, Kim HJ, Bae HM, Sim SH, Lee JO, Cha Y, Lee SH.
Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation. The
Korean Journal of Medicine 2009:77 (Supp 1) 188 ? 191.

Kim HJ, Kim MJ, Kim YJ, Han JH, Huh CH, Lee HS, Lee JS.
Rapidly progressing neurocutaneous melanosis (NCM) in a 49-year-old woman.
The Korean Journal of Medicine 2009 ; 77 (Supp 1) : p.183~187.

Sim SH, Kim HJ, Kim MJ, Cha Y, Lim KH, Lee SH.
Two cases of thyroid small cell carcinoma.
The Korean Journal of Medicine 2009:77:2:241 ? 245.

Kim SY, Kim HJ, Hong YS, Jung KH, Park JW, Choi HS, Oh JH, Park SJ, Kim SH, Nam BH,
Chang HJ, and Kim DY.
Resected colorectal liver metastases: Does the survival differ according to postoperative
chemotherapy regimen?
J Surg Oncol. 2009 Dec 15;100 (8):713-8

Kim HJ, Kim YJ, Seo MD, Yi HG, Lee SH, Lee SM, Kim DW, Yang SC, Lee CT, Lee JS, Kim YW,
Heo DS.
Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
Lung Cancer. 2009 Aug;65(2):242-6. Epub 2009 Jan 14.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2009 Jul;116(1):153-60. Epub 2008 Sep 12.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007 Nov 1;7:203.

2) Clinical Trials
(1) Representative list of participating clinical trials as co-investigator during last 3 years
1.Phase III multicenter Randomized Open-label study of irinotecan plus CapEcitabine versus capEcitabine in patients previously treateD with anthracycline and taxane for HER2 negative metastatic breast cancer [PROCEED]

2.Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

3. Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin in Cisplatin Un-fit Advanced Urothelial Carcinoma: Randomized PHase II Study (COACH Study)

4. A phase II study of TKI258 in patients with castration-resistant prostate cancer(CTKI258AKR03T)

5.A Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Patients With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as First-line Chemotherapy

6. A phase III sudy of ErbB2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapaitnib

7.Analysis of clinical outcome, predictive and prognostic factors of therapeutic responses in patients who treated with Doxorubicin & docetaxel neoadjuvant chemotherapy in clinical stage II or III Breast Cancer

8. Randomized, open label, phase III trial of CP-751,871 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer